TRS Stock Analysis: TriMas | NASDAQ
Packaging & Containers | NASDAQ, USA | Market Cap: 1.431m USD | 12M Return: 29.4% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 15.1M
EPS Trend: 34.6%
Qual. Beats: 0
Rev. Trend: -48.3%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
TriMas Corporation (NASDAQ: TRS) is a U.S.-based diversified industrial manufacturer that designs, develops, produces, and sells engineered products primarily for consumer products, aerospace and defense, and industrial end markets worldwide. The company operates through two reporting segments: Packaging, which supplies dispensing systems (pumps, sprayers), caps and closures, jar and bag-in-box products, and consumable vascular/diagnostic test components under brands such as Rieke, Taplast, Affaba & Ferrari, Aarts Packaging, Intertech, Omega Plastics, and Rapak; and Specialty Products, which makes and distributes steel cylinders for the storage and transport of compressed gases under the Norris Cylinder brand. TriMas distributes its products through a direct sales force supplemented by third-party agents and distributors, and was incorporated in 1986 with its headquarters in Bloomfield Hills, Michigan. The company is classified within the Industrials sector (Industrial Machinery & Supplies & Components sub-industry) and has a small-cap market capitalization.
The company follows a multi-brand, acquisition-driven industrial model typical of diversified industrial component makers, owning several niche product brands built through roll-ups (such as Rieke in dispensing and Norris Cylinder in gas containment) and selling across both OEM and aftermarket channels. TriMas went public via its 2007 IPO and has since pursued a strategy of operating focused, category-leading niche businesses rather than competing in large, commoditized industrial segments.
- Packaging segment revenue accelerates on healthcare component demand
- Steel cylinder orders track industrial production and energy investment
- Bolt-on acquisitions expand European packaging and aerospace exposure
| Net Income: 908.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.41 > 0.02 and ΔFCF/TA 37.16 > 1.0 |
| NWC/Revenue: 145.5% < 20% (prev 38.85%; Δ 106.6% < -1%) |
| CFO/TA 0.04 > 3% & CFO 88.9m > Net Income 908.5m |
| Net Debt (-827.7m) to EBITDA (181.2m): -4.57 < 3 |
| Current Ratio: 4.85 > 1.5 & < 3 |
| Outstanding Shares: last quarter (37.4m) vs 12m ago -8.65% < -2% |
| Gross Margin: 22.62% > 18% (prev 19.69%; Δ 2.93% > 0.5%) |
| Asset Turnover: 47.02% > 50% (prev 55.39%; Δ -8.37% > 0%) |
| Interest Coverage Ratio: 4.31 > 6 (EBIT TTM 80.8m / Interest Expense TTM 18.8m) |
| A: 0.55 (Total Current Assets 1.59b - Total Current Liabilities 327.5m) / Total Assets 2.30b |
| B: 0.40 (Retained Earnings 917.1m / Total Assets 2.30b) |
| C: 0.04 (EBIT TTM 80.8m / Avg Total Assets 1.85b) |
| D: 1.71 (Book Value of Equity 1.45b / Total Liabilities 847.3m) |
| Altman-Z'' = 7.00 = AAA |
| DSRI: 0.62 (Receivables 128.6m/183.8m, Revenue 867.8m/772.0m) |
| GMI: 0.87 (GM 19.69% / 22.62%) |
| AQI: 0.46 (AQ_t 0.19 / AQ_t-1 0.40) |
| SGI: 1.12 (Revenue 867.8m / 772.0m) |
| TATA: 0.36 (NI 908.5m - CFO 88.9m) / TA 2.30b) |
| Beneish M = -3.65 (Cap -4..+1) = AAA |
As of July 28, 2026, the stock is trading at USD 40.56 with a total of 380,985 shares traded. Over the past week, the price has changed by +1.58%, over one month by -8.89%, over three months by +8.03% and over the past year by +29.41%.
Current recommended Stop Loss: 38.10 (which is 6.1% or 2 ATR below the current price).
TriMas has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy TRS.
- StrongBuy: 1
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 45 | 10.9% |
P/E Trailing = 112.5833
P/E Forward = 23.8095
P/S = 2.4083
P/B = 0.9866
P/EG = 1.9395
Revenue TTM = 867.8m USD
EBIT TTM = 80.8m USD
EBITDA TTM = 181.2m USD
Long Term Debt = 396.6m USD (from longTermDebt, last quarter)
Short Term Debt = 7.19m USD (from shortTermDebt, last quarter)
Debt = 481.9m USD (from shortLongTermDebtTotal, last quarter) + Leases 42.7m
Net Debt = -827.7m USD (calculated: Debt 481.9m - CCE 1.31b)
Enterprise Value = 602.9m USD (1.43b + Debt 481.9m - CCE 1.31b)
Interest Coverage Ratio = 4.31 (Ebit TTM 80.8m / Interest Expense TTM 18.8m)
EV/FCF = 0.64x (Enterprise Value 602.9m / FCF TTM 937.3m)
FCF Yield = 155.5% (FCF TTM 937.3m / Enterprise Value 602.9m)
FCF Margin = 108.0% (FCF TTM 937.3m / Revenue TTM 867.8m)
Net Margin = 104.7% (Net Income TTM 908.5m / Revenue TTM 867.8m)
Gross Margin = 22.62% ((Revenue TTM 867.8m - Cost of Revenue TTM 671.5m) / Revenue TTM)
Gross Margin QoQ = 21.03% (prev 21.17%)
Tobins Q-Ratio = 0.26 (Enterprise Value 602.9m / Total Assets 2.30b)
Interest Expense / Debt = 3.89% (Interest Expense 18.8m / Debt 481.9m)
Taxrate = 24.07% (14.9m / 62.0m)
NOPAT = 61.3m (EBIT 80.8m * (1 - 24.07%))
Current Ratio = 2.67 (Total Current Assets 1.59b / Total Current Liabilities 594.7m)
Debt / Equity = 0.33 (Debt 481.9m / totalStockholderEquity, last quarter 1.45b)
Debt / EBITDA = -4.57 (Net Debt -827.7m / EBITDA 181.2m)
Debt / FCF = -0.88 (Net Debt -827.7m / FCF TTM 937.3m)
Total Stockholder Equity = 898.9m (last 4 quarters mean from totalStockholderEquity)
RoA = 49.23% (Net Income 908.5m / Total Assets 2.30b)
RoE = 101.1% (Net Income TTM 908.5m / Total Stockholder Equity 898.9m)
RoCE = 6.24% (EBIT 80.8m / Capital Employed (Equity 898.9m + L.T.Debt 396.6m))
RoIC = 3.17% (NOPAT 61.3m / Invested Capital 1.93b)
WACC = 7.17% (E(1.43b)/V(1.91b) * Re(8.59%) + D(481.9m)/V(1.91b) * Rd(3.89%) * (1-Tc(0.24)))
Discount Rate = 8.59% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -69.78 | Cagr: -4.61%
[DCF] Terminal Value 77.97% ; FCFF base≈582.7m ; Y1≈667.9m ; Y5≈983.0m
[DCF] Fair Price = 436.0 (EV 14.8b - Net Debt -827.7m = Equity 15.6b / Shares 35.8m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 34.59 | EPS CAGR: 3.36% | SUE: 0.62 | # QB: 0
Revenue Correlation: -48.35 | Revenue CAGR: -2.66% | SUE: 0.07 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.49 | Chg30d=+6.13% | Revisions=+40% | Analysts=2
EPS next Quarter (2026-09-30): EPS=0.52 | Chg30d=+1.56% | Revisions=+0% | Analysts=2
EPS current Year (2026-12-31): EPS=1.67 | Chg30d=+6.46% | Revisions=+40% | GrowthEPS=-20.0% | GrowthRev=-34.8%
EPS next Year (2027-12-31): EPS=2.17 | Chg30d=+4.33% | Revisions=+25% | GrowthEPS=+29.7% | GrowthRev=+5.0%
[Analyst] Revisions Ratio: +50% (up=6, down=1)